• Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN)
• HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies

BASEL, Switzerland and SY...